Recombinant ADAMTS13 Shows Superior Efficacy Over Plasma in Congenital TTP: A Paradigm Shift in Replacement Therapy – Blood Journals Portfolio
A recent study published by Blood Journals Portfolio (May 2024) available here demonstrates that recombinant ADAMTS13 (rADAMTS13) offers significantly more efficient ADAMTS13 replacement than traditional plasma infusions in patients with congenital thrombotic thrombocytopenic purpura (cTTP).
This finding marks a critical step forward in targeted therapy for patients with severe ADAMTS13 deficiency, a condition that leads to life-threatening microangiopathic hemolytic anemia and thrombocytopenia. Unlike plasma, which delivers ADAMTS13 in variable and limited concentrations, recombinant formulations offer predictable pharmacokinetics, higher bioavailability, and eliminate the risks associated with plasma-derived products, including allergic reactions and pathogen transmission.
These results underscore the potential of rADAMTS13 to become the standard of care in managing cTTP, improving prophylactic and acute-phase treatment outcomes.
Blood Journals Portfolio shared on X:
“Recombinant ADAMTS13 can supply ADAMTS13 more efficiently than plasma to patients with congenital thrombotic thrombocytopenic purpura.”
Title: Therapeutic switch from plasma to recombinant ADAMTS13 for patients with congenital TTP from Japanese real-world data
Autors: Kazuya Sakai, Atsushi Hamamura, Yoshiko Yoshimura, Miyuki Abe, Yoshiyuki Ogawa, Kazuki Tanaka, Norimichi Hattori, Tazuko Tokugawa, Rie Kanai, Fumiyoshi Ikejiri, Masahiro Takeyama, Teruhisa Taoka, Naoki Fujita, Minoru Kanaya, Katsuyoshi Koh, Hiroshi Shiragami, Hidekazu Azumi, Kenki Saito, Masanori Matsumoto
See more in-depth professional insights at Hemostasis Today, where we bring you the latest advances in thrombosis, hemostasis, and rare bleeding disorders.
-
Nov 19, 2025, 18:03Andres Ricaurte Fajardo on a Strongyloides Stercoralis Hyperinfection with Thrombosis
-
Nov 19, 2025, 17:50Marilena Vrana Reflects on PPTA Europe’s Visits with Members and Stakeholders in 2025
-
Nov 19, 2025, 17:32Michael Makris Shares Insights from Global Forum Meeting of the WFH Meeting in Montreal
-
Nov 19, 2025, 17:14Yazan Abou Ismail Takes The Legacy Award from Qatar Foundation
-
Nov 19, 2025, 17:02Wolfgang Miesbach Shares Real-World Evidence on Eptacog Beta from Spain
-
Nov 19, 2025, 16:34Ishita Singh Reflects on Haematocon 2025: A Reminder of Her Commitment to The Journey
-
Nov 19, 2025, 16:23Mehdi Kashani: I’m Really Excited to Share Schistosite.com
-
Nov 19, 2025, 16:09A ”Meow-cyte” from Melaku Abay Muluneh or Why Microscopy Never Gets Old!
-
Nov 19, 2025, 15:56Cuilan Li on her Contribution to a Cutting-Edge Project in Polycythemia Vera